GGrantIndex
Sort

51,593 grants matching hepatitis

Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass

$681,601
Ana Krtolica · Omniox, Inc. · R44 · FY2019 · HD

Club Drug Use and HIV Risks among Minorities in NYC

$681,596
Danielle C Ompad · New York Academy Of Medicine · R01 · FY2008 · DA

Development of a Urine Test for the Early Detection of Liver Cancer

$681,583
Surbhi Jain · Jbs Science, Inc. · R44 · FY2013 · CA

Development of a novel drug candidate that inhibits hepatitis B virus covalently

$681,531
Haitao Guo · Indiana University Indianapolis · R01 · FY2014 · AI

Metabolic Actions of FGF21

$681,470
Eleftheria Maratos-Flier · Beth Israel Deaconess Medical Center · R01 · FY2011 · DK

Ultra-Low Background NIR Fluorophores for In Vivo Imaging and Image-Guided Surger

$681,414
John V Frangioni · Beth Israel Deaconess Medical Center · R01 · FY2011 · EB

Risk Factors for Venous Thromboembolism in the Community

$681,242
John A Heit · Mayo Clinic Rochester · R01 · FY2012 · HL

Interaction of Chemical Carcinogens and Chemotherapeutic Agents with DNA

$681,204
Miriam C Poirier · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Smartphone Enabled Point-of-Care Detection of Serum Markers of Liver Cancer

$681,100
Ashutosh Chilkoti · Duke University · UH3 · FY2019 · CA

Evaluation of a community-based education, navigation, and support (CENS) intervention to reduce opioid-related harms among military veterans

$681,050
Alexander S Bennett · New York University · R01 · FY2023 · DA

Structural and Mechanistic basis for RNA Silencing

$681,013
Ian John Macrae · Scripps Research Institute, The · R35 · FY2023 · GM

3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)

$680,962
Heidi M. Crane · University Of Washington · U01 · FY2019 · AA

HEPATITIS C: STUDIES OF IMMUNITY AND PATHOGENESIS

$680,907
Rockefeller University · U19 · FY2000 · AI

Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

$680,901
Samuel Klein · Remd Biotherapeutics, Inc. · R42 · FY2018 · DK

The role of liver progenitor cells in liver regeneration

$680,900
Wolfram Goessling · Brigham And Women'S Hospital · R01 · FY2025 · DK

Integrating low-cost and versatile technologies to achieve colorimetric HCV and HIV detection from whole blood

$680,721
Jesse Waggoner · Emory University · R01 · FY2024 · AI

Hepatic stellate cells in liver homeostasis and regeneration

$680,622
Youngmin Anna Lee · Vanderbilt University Medical Center · R01 · FY2025 · DK

Understanding the Multilevel Drivers of Liver Cancer Disparities

$680,549
Salma Shariff-Marco · University Of California, San Francisco · R01 · FY2019 · CA

Them1-Mediated Metabolic Regulation and Pathogenic Role in NAFLD

$680,547
David E Cohen · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · DK

APO A-1 and Reverse Cholesterol Transport in Vivo

$680,520
Daniel James Rader · Children'S Hosp Of Philadelphia · P01 · FY2007 · HL

Delivery of Addiction Treatment for Medicaid Enrollees with Serious Injection-Related Infections

$680,423
Shashi Kapadia · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · DA

Development of FAPI PET as a Non-invasive Biomarker of Liver Fibrogenesis

$680,218
Ali Pirasteh · University Of Wisconsin-Madison · R01 · FY2025 · DK

Drug eluting injectable biomaterials for next generation chemoembolization

$680,198
Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2021 · CA

Systemically restricted 5-HT2B antagonists for pulmonary arterial hypertension

$680,115
William D Merryman · Vanderbilt University · R01 · FY2025 · HL

Testing of a Novel Inhaled Clofazimine (CFZ) Dry Powder Formulation in a Mouse Model of Mycobacterium tuberculosis

$680,009
Janice Endsley · University Of Texas Med Br Galveston · N01 · FY2023 · AI